One of the most important biomarkers for the diagnosis and long-term treatment of diabetes mellitus is haemoglobin A1c (HbA1c). By calculating the proportion of glycated haemoglobin in the blood it provides an indication of the average blood glucose levels during the previous two to three months. Poor glycaemic control and a higher risk of complications from diabetes, including neuropathy, nephropathy, and cardiovascular disease, are closely linked to elevated HbA1c levels. Because of this connection, HbA1c is a trustworthy measure for diabetes diagnosis as well as for tracking patient compliance and treatment efficacy. In order to lower complications and enhance patient outcomes, current clinical guidelines advise keeping HbA1c below particular thresholds. Effective disease management and prevention strategies require an understanding of the relationships between HbA1c levels and the progression of diabetes.
Hikmat Al‐Hashimi (Sun,) studied this question.